Trans Code Therapeutics Pitch Deck Teardown: Solving

Trans Code Therapeutics: A Deep Dive into RNA Oncology

Trans Code Therapeutics presents a technical and clinical-heavy investor deck that positions the company as a leader in the next generation of RNA-based oncology treatments. As a public company (NASDAQ: RNAZ), the deck's primary objective is to demonstrate the validity of its delivery platform and the progress of its clinical pipeline. The presentation is structured to address the most significant bottleneck in the RNA space: delivery.

The Platform and the Problem

Slide 1: Title Slide The deck opens with a clear branding statement: "The RNA Oncology Company." It prominently displays the NASDAQ symbol "RNAZ," immediately signaling to the viewer that this is a public entity. The design is clean and clinical, utilizing a DNA sequence background that reinforces the company's focus on genetic medicine.

Slide 5: TTX-Based Modular Design Toolbox This slide introduces the core of Trans Code's value proposition. The company describes a "Modular Design Toolbox" that allows them to synthesize libraries of therapeutic agents. The toolbox is categorized into four segments: Blueprint (annotated genetic code), Modular (therapeutic oligonucleotides), Tunable (nanocarrier delivery mechanism), and Image Guided (imaging for measurement). Crucially, the slide lists RNAi, PRR, CRISPR, and mRNA Vaccine as components that can be optimized using this platform. This suggests a broad horizontal platform play rather than a single-drug vertical.

Slide 9: The Delivery Challenge Trans Code identifies the "elephant in the room" for RNA therapeutics: delivery outside the liver. They state that their strategy employs a nanoparticle previously used in imaging, now repurposed to deliver oligonucleotides to tumors and metastases. The slide emphasizes that overcoming this delivery hurdle is the key to unlocking access to a variety of genetic targets in a range of cancers. This slide serves as the "Problem" slide, but framed through a technical lens.

Lead Candidate: TTX-MC138

Slide 13: Addressing High Unmet Need in Metastatic Cancer The company focuses its lead candidate, TTX-MC138, on metastatic disease. Citing that 10 million people died from cancer in 2020 (mostly due to metastasis), they position microRNA-10b as the "master regulator" of this progression. The slide highlights preclinical results showing the inhibition of miR-10b led to the regression of established metastases in mice with no recurrence or toxicity. This is a high-stakes claim backed by the promise of an expedited regulatory path.

Slide 17: Preclinical Evidence of Delivery This slide provides the visual proof of their delivery claims. It features imaging of drug accumulation in the lymph nodes, lungs, bone, and brain metastases. By showing the drug co-localized with metastatic lesions, Trans Code attempts to prove that their "Tunable" nanocarrier is actually reaching the intended targets outside the liver. The inclusion of brain metastasis imaging is particularly notable, as the blood-brain barrier is a notorious obstacle for most therapeutics.

Clinical Roadmap and Next Steps

Slide 21: Phase 0 Trial Design Trans Code outlines a very specific Phase 0 study for TTX-MC138. The study targets 10 Stage IV breast cancer patients who will receive a single 100 microgram dose. The primary goal is pharmacokinetic: using PET-MRI or PET-CT to quantify delivery to lesions. This is a strategic move to de-risk the platform in humans before committing to the massive expense of Phase I/II trials. The slide includes a chemical diagram of 64Cu-TTX-MC138, further emphasizing the technical maturity of the project.

Slide 25: Next Steps The roadmap is divided into two clear paths: the Exploratory IND for Phase 0 and the IND for Phase I/II. The company lists specific manufacturing and regulatory milestones, such as completing CMC (Chemistry, Manufacturing, and Controls) processes and CMO (Contract Manufacturing Organization) validation. This slide is essential for investors to understand the immediate timeline for value inflection points.

The Addendum and Future Pipeline

Slide 29: Addendum Slides This acts as a transition to the broader pipeline, listing candidates in development including PD-L1, Lin28b, RIG-I, CRISPR, and mRNA vaccines. It reinforces the "platform" narrative established in Slide 5.

Slide 33: TTX-siPDL1 and RNAi Advantages This slide compares Trans Code's approach to traditional checkpoint inhibitors. While current drugs block the binding of PD-1/PD-L1, Trans Code's RNAi approach is intended to prevent the synthesis of PD-L1 entirely. The visual diagrams contrast "Traditional" vs. "RNAi" mechanisms, making a case for why their method might work in cancers like pancreatic cancer where others have failed.

Slide 37: CRISPR/Cas9 Cancer Therapy The final slide in the provided set illustrates the potential for the TTX platform to deliver CRISPR/Cas9. It shows the mechanism for deleting faulty genes or repairing cancer-causing sequences. While likely in the very early stages, this slide signals the company's long-term ambition to be a delivery vehicle for the most advanced gene-editing tools available.

What Works in This Deck

Technical Clarity: The deck does an excellent job of identifying a specific technical problem (liver-restricted delivery) and explaining exactly how their platform solves it. · Visual Evidence: The use of PET imaging and microscopy in Slide 17 provides tangible proof of the company's claims, which is vital in biotech. · Strategic De-risking: The focus on a Phase 0 microdosing study (Slide 21) shows a sophisticated approach to clinical development that seeks to prove delivery in humans quickly and cost-effectively. · Platform Breadth: By showing applications for RNAi, CRISPR, and vaccines, the company isn't just a "one-trick pony"; it’s a delivery engine that could be applied to many different therapeutic areas.

What Is Missing

Team and Leadership: The provided slides contain no information about the founders, the scientific advisory board, or the management team. In biotech, the pedigree of the scientists is often as important as the data. · Financials and Ask: There is no mention of the company's cash runway, current burn rate, or a specific request for capital. While this is common for a general investor presentation for a public company, it leaves a gap for a potential investor looking for a deal structure. · Competitive Landscape: The deck assumes the viewer knows the other players in the RNA space. A slide comparing their delivery efficiency or targeting capabilities against competitors (like Alnylam or Ionis) would have been beneficial. · Market Size by Indication: While they mention 10 million deaths, they don't break down the specific Total Addressable Market (TAM) for their lead indications in breast cancer or pancreatic cancer.

Founder Takeaways

Lead with the Bottleneck: If your industry has a well-known technical hurdle, address it head-on. Trans Code’s focus on "delivery outside the liver" immediately tells an informed investor why this company matters. · Use Addendum Slides for Breadth: Keep your main narrative focused on your lead candidate (TTX-MC138) but use an addendum to show the platform's versatility. This prevents the deck from feeling unfocused while still showing upside. · Visualize the Data: In deep tech or life sciences, a single slide of imaging data (like Slide 17) is worth more than ten slides of bullet points. If you have the data, show it. · Define the Regulatory Path: Don't just say you are going to clinical trials. Detail the specific study design, patient count, and endpoints as seen in Slide 21. It demonstrates operational maturity.